MCF Advisors LLC Purchases 12 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

MCF Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36 shares of the biopharmaceutical company’s stock after acquiring an additional 12 shares during the period. MCF Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $32,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ronald Blue Trust Inc. increased its stake in Regeneron Pharmaceuticals by 18.8% during the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 12 shares during the period. Drive Wealth Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 4.0% in the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 12 shares during the period. Sutton Wealth Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares during the period. Clearview Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 13 shares during the period. Finally, Smithfield Trust Co grew its stake in shares of Regeneron Pharmaceuticals by 11.0% in the 3rd quarter. Smithfield Trust Co now owns 141 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 14 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. Truist Financial reiterated a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. UBS Group upped their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Cantor Fitzgerald restated a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, April 15th. Finally, BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $976.41.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $900.16 on Tuesday. The business’s fifty day moving average is $952.07 and its 200-day moving average is $892.70. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The company has a market cap of $98.80 billion, a P/E ratio of 25.90, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm’s revenue was up .6% compared to the same quarter last year. During the same quarter last year, the business posted $10.96 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the sale, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the transaction, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,022 shares of company stock valued at $10,552,991. 8.83% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.